Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVT02 vs Humira PK Study
NCT03849313Phase 1Completed
- Sponsor
- Alvotech
- Start
- Mar 2019
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of AVT02 in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and 1 more (3 arms), sponsored by Alvotech. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last quantifiable concentration at Day 64, Maximum serum concentration at Day 64 and 1 more. Started Mar 2019; status: completed.
02
Drugs
AVT02
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)plaque psoriasis
Beyond the preview
Go deeper on NCT03849313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03849313.